Imaging has become a cornerstone of clinical research, not only in oncology but across a wide range of therapeutic areas. Whether assessing tumour response in cancer, cardiac function in heart disease, or neurodegenerative changes in Alzheimer’s, imaging-derived endpoints—such as lesion volume, myocardial perfusion, or tumour progression—are critical for evaluating treatment efficacy and safety.
For sponsors, Contract Research Organisations (CROs), and healthcare professionals, managing image acquisition, exchange, and analysis across global sites presents significant challenges. This complexity can be managed effectively through a robust image exchange solution and the scientific expertise of centralised reading facilities (CoreLabs). Together, they ensure compliance with regulatory authorities such as the EMA and FDA while delivering high-quality, reproducible data.
Strategic role of CoreLabs in clinical trials
CoreLabs are more than merely service providers. They act as scientific partners embedded within the imaging workflows of clinical trials. Through centralised image review, rigorous quality control, and the application of standardised assessment criteria, CoreLabs ensure unbiased and consistent image interpretation.
This approach is essential in studies where imaging determines primary or secondary endpoints and is equally valuable for confirming patient eligibility or assessing imaging-related adverse events. By unifying imaging standards and minimising site-to-site variability, CoreLabs enhance the scientific integrity and reliability of trial data.
Why professional image exchange solutions are essential
High-quality expert review begins with secure and efficient image exchange. Clinical trials often involve hundreds or even thousands of DICOM images (MRI, PET, CT, or ultrasound) collected at multiple time points across diverse global sites. Without a regulatory-compliant and user-friendly platform, managing this process can quickly become a logistical and compliance challenge.
Professional image exchange solutions, like decidemedical, address these challenges by offering:
- Regulatory-compliant DICOM transfer (GDPR, HIPAA, 21 CFR Part 11)
- Zero local installations, minimising IT burdens at clinical sites
- Integrated DICOM previewers for real-time quality control
- Built-in communication tools for quick issue resolution
- Role-based access to ensure safe and timely image delivery
- Comprehensive audit logs to maintain traceability and trial data integrity
Not all trials are identical, but the need for efficient imaging workflows is universal, regardless of their focus on oncology, cardiology, neurology, or musculoskeletal diseases.
Aligning central reading with advanced imaging protocols
A robust exchange platform is only half of the solution. The other half is the central readers’ expertise. Central readers are highly trained in the specific imaging modalities and criteria of their respective therapeutic areas. Their knowledge is critical for accurate, reproducible image interpretation, especially in studies using advanced or quantitative imaging techniques.
- Oncology: Distinguishing true progression from pseudoprogression often requires advanced MRI techniques such as perfusion MRI (pMRI) or diffusion-weighted MRI (DWI).
- Cardiovascular Medicine: Assessing structural heart diseases or vascular lesions relies on MDCT, MRI, echocardiography or angiographic analysis.
- Neurology: Monitoring neurodegenerative diseases often involves PET or MRI scans to measure amyloid plaque burden or brain volume changes.
- Musculoskeletal Research: Evaluating joint degradation or bone density typically employs quantitative CT (QCT) or high-resolution peripheral QCT (HR-pQCT). PET/CT may be used to assess inflammatory or metastatic activity.
Equally important is imaging protocol harmonisation across all sites. Standardising image acquisition parameters and calibrating scanners minimises variability, ensuring data consistency and reliability.
Sponsor Benefits: A Unified Imaging Ecosystem for All Trials
By combining a professional image exchange solution with a strategic CoreLab partnership, sponsors gain an end-to-end ecosystem that enhances operational efficiency, scientific credibility and regulatory compliance.
Key benefits include:
- Accelerated read timelines through real-time notifications and quality assurance (QA) workflows
- Improved endpoint accuracy through specialised central readers
- Full regulatory compliance with audit trails and standardised protocols
- Enhanced site experience through simplified uploads and fewer manual queries
Conclusion: Imaging-Driven Trials Need Imaging-Driven Partnerships
As imaging becomes increasingly central to clinical research across all therapeutic areas, the demand for project-specific, technology-driven imaging workflows continues to rise. Sponsors, CROs, and healthcare professionals who invest in strategic CoreLab partnerships and advanced image exchange solutions are best positioned to produce high-quality, regulatory-compliant data and accelerate time to market.
It is no longer enough to simply collect medical images. Success depends on transforming imaging data into actionable insights. That starts with the right partnerships and technologies, tailored to your project’s unique needs.
Your clinical trials are imaging-driven? Let’s make them successful.
Contact us today to learn more.
